Troubled Novelos touts promising breast cancer data

After suffering a serious setback when NOV-002 flunked a late-stage clinical trial for lung cancer earlier this year, Novelos says the same drug proved effective in combination with chemotherapy during a small Phase II trial for breast cancer. But the news failed to inspire much hope among disillusioned investors. Its shares (NVLT) were trading at 14 cents this morning. "We are excited about this proof of concept trial and we are excited to have NOV-002 back in the game," Novelos CEO Harry...

Live from BIO 2010: A human face for the drug industry

Yesterday I left Philadelphia for FierceBiotech's annual trip to BIO. The 2010 conference is being held in Chicago where, over the next four days, FierceBiotech and FiercePharma will bring you live coverage of this year's event. I always look forward to covering sessions and speaking with industry experts about the lastest trends in the drug development world. But as it turned out, my first interview would be conducted not at the show, but in the shuttle to the airport. Ashley...